Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-03	$0.4350	0.00%	34,200
26-07-02	$0.4350	-1.14%	38,620
26-06-30	$0.4400	0.00%	34,500

Delayed Quote Canadian Securities Exchange

More quotes

Income Statement and Estimates

More financial data

Delayed Canadian Securities Exchange Other stock markets 14:20:25 2026-07-03 EDT			5-day change	1st Jan Change
0.4350 ^CAD	0.00%		-13.00%	-39.58%

06-03	Defence Therapeutics Inc. Announces Appointment of John Beaver to Its Board of Director	CI
06-01	Defence Therapeutics Inc. Appoints Dr. John Lambert as Board Director, Effective 1 June 2026	CI

Market Cap	33.35M 23.48M 20.52M 18.86M 17.58M 2.24B 33.85M 226M 88.03M 1.1B 88.13M 86.23M 3.79B	P/E 2024	-2.5x	P/E 2025	-9.9x
Enterprise Value	33.62M 23.67M 20.69M 19.02M 17.72M 2.25B 34.13M 228M 88.74M 1.11B 88.84M 86.94M 3.82B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	66.13%	Yield 2024 *	-	Yield 2025	-

06-03	Defence Therapeutics Inc. Announces Appointment of John Beaver to Its Board of Director	CI
06-01	Defence Therapeutics Inc. Appoints Dr. John Lambert as Board Director, Effective 1 June 2026	CI
05-29	Defence Therapeutics Inc. Announces Resignation of Dr. Sarkis Meterissian from Board, Joins Scientific Advisory Board	CI
05-22	Defence Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
05-19	Defence Therapeutics Inc Expands In-House Adc Development Platform with Enhanced Analytical and Cellular Testing Capabilities	CI
03-05	Defence Therapeutics Inc. announced that it has received CAD 9.595 million in funding	CI
02-26	Defence Therapeutics Inc. announced that it expects to receive CAD 11 million in funding	CI
02-20	Defence Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025	CI
01-28	Defence Therapeutics Expands Collaboration With Canadian Nuclear Laboratories	MT
01-28	Defence Therapeutics Inc. Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline	CI
12-04	Defence Therapeutics Inc. Announces the Formation of Its Inaugural Scientific Advisory Board	CI
11-27	Defence Therapeutics Inc. Reports Earnings Results for the First Quarter Ended September 30, 2025	CI
11-19	Defence Therapeutics Inc. to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology	CI

06-17	Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions	NE
06-03	Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors	NE
06-01	Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors	NE
05-29	Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian	NE
05-19	Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities	NE

Defence Therapeutics Inc. Stock

Stocks

DTC

CA24463V1013

Biotechnology & Medical Research

Valuation: Defence Therapeutics Inc.

Chart: Defence Therapeutics Inc.

Latest news : Defence Therapeutics Inc.

Press Releases: Defence Therapeutics Inc.

News in other languages: Defence Therapeutics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Defence Therapeutics Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

24-08-19	DEFENCE UNTERSUCHT DIE ANWENDUNG DER ACCUM®- HYDROGELTECHNOLOGIE ZUM TRANSPORT VON GLP-1 ZWECKS VERBESSERUNG DER WIRKSAMKEIT DER BEHANDLUNG VON DIABETES UND ZUM ERZIELEN EINES GEWICHTSVERLUSTS
24-08-13	KOOPERATIONSVEREINBARUNG VON DEFENCE THERAPEUTICS MIT ORANO ZUR ENTWICKLUNG DER NÄCHSTEN GENERATION DER GEZIELTEN RADIOIMMUNTHERAPIE FÜR FORTSCHRITTE BEI DER KREBSBEKÄMPFUNG
24-07-24	DEFENCE THERAPEUTICS ERHÄLT UNTERSTÜTZUNG DURCH DAS CNRI-H-PROJEKT VON CANADIAN NUCLEAR LABORATORIES ZUR BESCHLEUNIGUNG DER ENTWICKLUNG SEINES RADIOIMMUNOKONJUGAT-PROGRAMMS
24-07-08	DEFENCE ERHÄLT ‚NO OBJECTION LETTER’ VON DER KANADISCHEN GESUNDHEITSBEHÖRDE HEALTH CANADA FÜR SEINE PHASE I-STUDIE MIT ACCUM-002 (ACCUTOX) ALS MOLEKÜL ZUR KREBSBEKÄMPFUNG BEI PATIENTEN MIT MELANOMEN
24-07-01	ACCUTOX VON DEFENCE VERSTÄRKT DIE WIRKUNG VON IMMUNCHECKPOINTINHIBITOREN UND SCHAFFT SO SYNERGIEEFFEKTE

1 week	-13.00%
Current month	-1.14%
1 month	-14.71%
3 months	-16.35%
6 months	-36.96%
Current year	-39.58%

1 week	0.41	0.46
1 month	0.41	0.55
Current year	0.41	0.74
1 year	0.41	0.93
3 years	0.41	3.04
5 years	0.41	8.15
10 years	0.41	8.15

Manager	Title	Age	Since
Sébastien Plouffe CEO	Chief Executive Officer	53	2024-09-26
Arnab De DFI	Director of Finance/CFO	55	2024-12-19
Maxime Parisotto CTO	Chief Tech/Sci/R&D Officer	-	2024-11-24

Director	Title	Age	Since
Sébastien Plouffe BRD	Director/Board Member	53	2020-06-01
Sarkis Meterissian BRD	Director/Board Member	64	2021-01-04
Philippe Lefrancois BRD	Director/Board Member	-	2024-09-26

Date	Insider	Type	Main position	Quantity	% Market Cap.
06-02	John Beaver	Other	Director	0	0%
06-02	John Beaver	Option	Director	150,000	0.1979%
05-31	John Lambert	Other	Director	0	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DEFENCE THERAPEUTICS INC.	0.00%	-13.00%	-40.41%	-85.50%	23.21M
LONZA GROUP AG	+0.35%	+7.01%	+3.48%	+9.27%	49.92B
REVOLUTION MEDICINES, INC.	+1.73%	+0.41%	+427.43%	+638.21%	40.23B
IQVIA HOLDINGS INC.	-0.81%	+6.39%	+26.58%	-5.52%	34.55B
BEONE MEDICINES AG	+3.52%	+6.08%	+27.65%	+62.40%	33.09B
CELLTRION, INC.	-4.19%	+6.03%	+3.76%	+32.17%	27.51B
ASCENDIS PHARMA A/S	-1.89%	+1.83%	-	-	17.05B
MEDPACE HOLDINGS, INC.	-0.19%	+4.66%	+75.49%	+139.19%	15.92B
EUROFINS SCIENTIFIC SE	-0.89%	+0.82%	+14.03%	+21.66%	13.86B
IONIS PHARMACEUTICALS, INC.	+2.30%	+3.21%	+99.33%	+99.43%	13.52B
Average	-0.03%	+3.85%	+70.82%	+101.26%	24.57B
Weighted average by Cap.	+0.15%	+6.42%	+96.42%	+143.27%

	2024	2025
Net sales	-	-
Net income	-13.19M -9.29M -8.12M -7.46M -6.96M -884M -13.39M -89.59M -34.83M -435M -34.87M -34.12M -1.5B	-3.52M -2.48M -2.17M -1.99M -1.86M -236M -3.58M -23.92M -9.3M -116M -9.31M -9.11M -400M
Net Debt	1.69M 1.19M 1.04M 956K 891K 113M 1.72M 11.48M 4.46M 55.68M 4.47M 4.37M 192M	272K 191K 167K 154K 143K 18.22M 276K 1.85M 718K 8.96M 718K 703K 30.87M